Literature DB >> 16224621

[Memantine as an adjunctive therapy for schizophrenia negative symptoms].

Clarissa Severino Gama, Paula Antunes, Carolina Moser, Paulo Silva Belmonte-de-Abreu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16224621     DOI： 10.1590/s1516-44462005000300023

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN： 1516-4446            Impact factor:   2.697


× No keyword cloud information.
  5 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

2.  Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study.

Authors:  Jung Goo Lee; Sae Woom Lee; Bong Ju Lee; Sung Woo Park; Gyung Mee Kim; Young Hoon Kim
Journal:  Psychiatry Investig       Date:  2012-05-22       Impact factor: 2.505

Review 3.  Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Authors:  Maria D Rubio; Jana B Drummond; James H Meador-Woodruff
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

4.  Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders.

Authors:  Maria Tavakoli-Ardakani; Hamide Abbaspour; Abdollah Farhadi Nasab; Azadeh Mazaheri Meibodi; Ali Kheradmand
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

5.  Tackling negative symptoms of schizophrenia with memantine.

Authors:  Antonios Paraschakis
Journal:  Case Rep Psychiatry       Date:  2014-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.